Belvedere Trading
AKBA icon

Belvedere Trading’s Akebia Therapeutics AKBA Stock Holding History

Belvedere Trading’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100
Closed -$58 – 896
2022
Q4 		$58 Buy
+100
New +$31 ﹤0.01% 1116

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Belvedere Trading's AKBA Position: Q1 2023 in Review

Belvedere Trading sold out of Akebia Therapeutics (AKBA) in Q1 2023, closing a stake of 100 shares — an estimated $58 sold.

Belvedere Trading first reported a position in AKBA in Q4 2022 and held it in 1 quarter. The position peaked at $58 in Q4 2022. 65 funds tracked by Wall St. Rank hold AKBA as of Q1 2023.

  • Belvedere Trading reported no remaining Akebia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 100 Akebia Therapeutics shares in Q1 2023, an estimated $58.
  • Belvedere Trading first reported a position in Akebia Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belvedere Trading's Akebia Therapeutics position peaked at $58 in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.